VDAC1 and Myocardial fibrosis: Our findings also indicate that pharmacological inhibition of VDAC1 activity can have beneficial effects in preventing the formation of fibrosis in the diseased myocardium and, thus, may serve as a new therapeutic option in various cardiac pathologies that are characterized by excessive myocardial fibrosis.